The experiment was designed around a deceptively simple question: when a parent plant has experienced elevated ultraviolet-B radiation, do its offspring behave differently, and does that difference depend on the kind of environment the offspring find themselves in? UV-B radiation, the short-wavelength portion of sunlight that reaches Earth’s surface, is a potent environmental stressor for plants. It damages DNA, triggers the production of protective pigments, and alters patterns of growth and development. But natural environments are rarely uniform. Sunlight filters through canopy gaps, falls in shifting patches across a forest floor, and varies dramatically from one square meter to the next. The researchers reasoned that a parental memory of UV-B exposure would only be useful to offspring if it could be deployed in a way that matched the actual pattern of UV-B they encountered — and that testing this would require exposing offspring to two fundamentally different kinds of patchy environments.

To do this, the team first exposed parent ramets of Glechoma longituba, a stoloniferous clonal herb common in China, to UV-B radiation. Some parent plants were also treated with 5-azacytidine, or 5-Azac, a well-established demethylation agent that chemically strips methyl groups from DNA. This pharmacological approach is the key to the study’s mechanistic ambition: if parental UV-B effects on offspring depend on DNA methylation, then erasing methylation marks in the parent should abolish or alter those effects. The offspring generation was then grown under two types of heterogeneous UV-B environments. In the first, designated Re, UV-B-rich and UV-B-free patches alternated in a regular, predictable pattern. In the second, designated Ra, patches were distributed randomly, so offspring could not anticipate where high or low radiation would occur. This design allowed the researchers to separate the influence of parental experience from the influence of environmental pattern — a distinction that most studies of parental effects have never attempted.

The results were unambiguous on the first point: parental UV-B exposure significantly enhanced clonal growth in the offspring generation. But the way that enhancement was expressed depended entirely on the pattern of the offspring environment. In the regularly alternating environment, offspring from UV-B-treated parents shifted their strategy underground, increasing allocation to below-ground biomass while simultaneously boosting photosynthetic capacity above ground. This combination suggests a plant preparing for sustained competition and resource capture — building a stronger root system while improving its ability to harvest light when it encounters favorable patches. In the randomly distributed environment, the same parental history produced a completely different phenotype: offspring elongated their secondary branch stolons, the horizontal runners from which new ramets sprout, and allocated more of their ramets to control patches with low or no UV-B. In other words, the plants used their inherited information to escape, placing their descendants where the radiation threat was lowest.

The contrast between these two strategies is what makes the study remarkable. A regularly alternating environment is predictable: a plant that can detect the rhythm of high and low UV-B can plan its growth accordingly, investing in structures that will pay off over the long term. A random environment offers no such predictability, so the optimal strategy becomes one of risk avoidance — spreading stolons rapidly and concentrating new growth in the safest available patches. The parental UV-B experience did not simply make offspring tougher or faster-growing in a general sense; it equipped them with a flexible toolkit whose deployment was calibrated to the statistical structure of the environment they faced. This is pattern-dependent plasticity, and it implies that the parental effect encodes something more sophisticated than a blanket stress response.

The pharmacological arm of the experiment delivered the study’s most provocative finding. When parents were treated with 5-azacytidine, many of the parental UV-B effects were abolished outright, and some were reversed. Offspring whose parents had received both UV-B and the demethylation agent failed to show the enhanced clonal growth, the altered biomass allocation, and the strategic ramet placement that characterized offspring of UV-B-exposed parents alone. Because 5-azacytidine acts by removing methyl groups from cytosine bases in DNA, the most parsimonious interpretation is that DNA methylation patterns established or modified by the parental UV-B experience are what carry the environmental memory into the next generation. The authors are careful to frame this as implicating methylation rather than proving it definitively — the agent can have off-target effects, and the study did not directly sequence methylated regions of the genome — but the pattern of abolition and reversal is exactly what a methylation-mediated mechanism would predict.

DNA methylation is an attractive candidate for transgenerational environmental memory in plants for several reasons. Unlike genetic mutations, methylation marks can be established rapidly in response to environmental cues, yet some of them persist through cell division and even through meiosis, allowing them to be inherited by offspring without any change in DNA sequence. In clonal plants like Glechoma longituba, which reproduce vegetatively through stolons and ramets, epigenetic states can propagate across physically connected generations with particular fidelity. This raises the possibility that clonal plant populations, which often dominate the ground layer of forests, grasslands, and disturbed habitats, may possess a form of collective memory: older ramets that have weathered UV-B stress could prime younger ramets to respond appropriately, with the response tuned to the spatial predictability of the radiation environment. Such a mechanism would have profound implications for how plant populations cope with rising UV-B levels, which have been increasing in many regions as stratospheric ozone recovery remains uneven.

The study also fills a conceptual gap in the parental effects literature. Ecologists have documented parental environmental effects in dozens of species, showing that offspring of stressed parents are often more tolerant of the same stress. But nearly all of these studies expose offspring to uniform conditions. By manipulating the spatial pattern of the offspring environment, Quan and colleagues have shown that the expression of parental effects is itself context-dependent — that the same inherited information can produce opposite phenotypic outcomes depending on whether the environment is regular or random. This adds a layer of complexity that models of plant adaptation will need to incorporate. It also suggests that experiments conducted in homogeneous greenhouse conditions may systematically underestimate or mischaracterize the parental effects that operate in nature, where heterogeneity is the rule rather than the exception.

The practical implications extend beyond ecology into agriculture. Many crop plants are clonally propagated, including potatoes, cassava, sugarcane, and numerous fruit species, and epigenetic variation in clonal crops is already known to influence yield and stress tolerance. If parental UV-B experience can prime offspring growth strategies through methylation-dependent mechanisms, then the growing conditions of mother plants in propagation programs could be deliberately managed to produce seedlings or ramets better suited to the light environments they will face in the field. Conversely, the finding that a demethylation agent can erase these primed responses underscores how sensitive such epigenetic legacies may be to chemical and environmental perturbation, with consequences for both agricultural practice and the conservation of wild clonal populations.

The authors acknowledge that further molecular evidence is required to verify the causal role of DNA methylation, and future work will likely involve genome-wide methylation profiling of parent and offspring ramets to identify the specific loci whose methylation states change in response to UV-B and correlate with the observed growth strategies. Such studies would also reveal whether the methylation marks are targeted at genes involved in UV-B signaling, photosynthesis, stolon development, or broader regulatory networks. For now, the study stands as an elegant demonstration that the boundary between generations is more permeable than classical genetics suggests, and that plants may carry within their genomes a chemical record of the sunlight their parents endured. In a world where radiation regimes, canopy structures, and climate patterns are all shifting, that record may prove to be one of the most valuable inheritances a plant can receive.

Subject of Research: Transgenerational parental effects of UV-B radiation mediated by DNA methylation in the clonal plant Glechoma longituba

Article Title: Parental UV-B experience implicates DNA methylation in divergent offspring growth strategies under heterogeneous UV-B patterns in a clonal plant

Article References: Quan, J., Zhou, X., Zhang, S., Hu, D., Yang, Y., Liu, X., & Yue, M. (2026). Parental UV-B experience implicates DNA methylation in divergent offspring growth strategies under heterogeneous UV-B patterns in a clonal plant. BMC Plant Biology. https://doi.org/10.1186/s12870-026-10006-w

Image Credits: AI Generated

DOI: 10.1186/s12870-026-10006-w

Keywords: UV-B radiation, parental effects, DNA methylation, epigenetics, clonal plants, Glechoma longituba, 5-azacytidine, environmental heterogeneity, phenotypic plasticity, transgenerational memory, plant biology, stolons

The story begins with the molecule itself. 5-Azacytidine is a mimic of cytidine, one of the four canonical letters of RNA, but with a crucial difference: the carbon at position 5 of the pyrimidine ring is replaced by nitrogen, converting the base into 5-azacytosine, a member of the 1,3,5-triazine family. This single atom swap is what gives the drug its therapeutic power. Once incorporated into RNA, the analogue disrupts RNA metabolism and traps methyltransferase enzymes, ultimately reactivating tumor suppressor genes that cancer cells had silenced. Approved by the FDA in 2004 under the brand name Vidaza, the compound has become a mainstay of treatment for patients with myelodysplastic syndromes.

Because the drug was first made synthetically by Czech chemists in 1964 and only isolated from microbial cultures two years later, most researchers assumed its biosynthesis would never be found, or simply never thought to look. The prevailing view treated 5-azacytidine as a synthetic analogue that happened to also occur in nature, rather than as the product of an evolved metabolic pathway. That assumption, the new work shows, hid one of the most unusual enzymatic cascades yet discovered in natural product chemistry.

A team led by Yasushi Ogasawara and Tohru Dairi of Hokkaido University, together with Hiroyuki Morita of the University of Toyama and collaborators across Japan and Taiwan, set out to find the gene cluster. Through comparative genomics and biochemical screening of the producing organism, they pinpointed a set of genes designated azc that is both necessary and sufficient for assembling the triazine nucleobase. The identification immediately posed a puzzle: how does a cell convert ordinary purine and pyrimidine building blocks into a ring system with an extra nitrogen in an arrangement that is otherwise essentially unknown among natural nucleosides?

The answer begins with AzcE, an enzyme the researchers identify as a guanosine triphosphate cyclohydrolase. GTP cyclohydrolases are best known for opening the purine ring of GTP during the biosynthesis of folate and riboflavin, but AzcE repurposes this chemistry to generate 2,5,6-triaminopyrimidin-4(1H)-one, a pyrimidine intermediate carrying three amino groups. Structural analysis of AzcE, determined in complex with zinc and its product, revealed how the enzyme positions the substrate for ring opening, providing the first stepping stone on the path from a standard nucleotide precursor toward the triazine scaffold of the drug.

The centerpiece of the pathway, and of the study, is AzcA, a cupin domain-containing enzyme that performs what the authors describe as a skeletal editing reaction. Rather than building the triazine ring from scratch, AzcA takes the pyrimidine delivered by AzcE and surgically reworks it: the enzyme selectively cleaves the carbon-nitrogen framework of the heterocycle and reassembles it into 6-amino-4-oxo-1,4-dihydro-1,3,5-triazine-2-carboxylic acid. In effect, the protein performs molecular surgery on a ring, cutting specific bonds and stitching the fragments back together with an additional nitrogen inserted into the skeleton. X-ray crystal structures of AzcA bound to manganese and to reaction intermediates, combined with biochemical assays and density functional theory calculations, allowed the team to trace the mechanism in atomic detail, showing how the metal center and active-site residues orchestrate bond cleavage and reformation with remarkable selectivity.

The final step is equally unconventional. The carboxylic acid that AzcA installs must be removed to yield 5-azacytosine, and the enzyme pair AzcB/C accomplishes this through a thiamine pyrophosphate-dependent decarboxylation acting on the alpha-imino carboxylic acid moiety of the AzcA product. Thiamine-dependent enzymes typically handle alpha-keto acids, so acting on an imino acid represents an atypical use of this cofactor class. Cryo-electron microscopy structures of AzcB/C captured with thiamine pyrophosphate and substrate analogues revealed the active-site architecture that stabilizes the reactive intermediates, completing the mechanistic picture of how the triazine base is finished and presumably glycosylated to give the mature nucleoside antibiotic.

What makes the discovery resonate beyond one molecule is the concept of enzymatic skeletal editing itself. Synthetic chemists have in recent years celebrated skeletal editing, the late-stage insertion, deletion, or transmutation of single atoms within a molecular framework, as a frontier strategy for drug discovery. The demonstration that a cupin enzyme performs precisely this kind of single-atom logic on a heterocyclic ring during natural biosynthesis shows that nature arrived at the same idea long ago, and suggests that related enzymes scattered across bacterial genomes may perform similar transformations on other scaffolds. Genome mining guided by the azc gene cluster could therefore uncover new triazine and related azine natural products, or inspire engineered enzymes for late-stage functionalization of existing drugs.

There are also practical implications for the drug itself. Current industrial production of 5-azacytidine relies on multi-step chemical synthesis, and a biosynthetic route defined by just a handful of enzymes offers a potential platform for biocatalytic or fermentative manufacturing, possibly enabling access to analogues that are difficult to make chemically. The work also resolves a long-standing oddity in natural product history: a molecule used daily in oncology wards worldwide turns out to be a genuine bacterial metabolite, forged by enzymes that edit the very skeletons of nucleobases. For a drug whose clinical value stems from impersonating DNA’s own letters, it is fitting that its maker turns out to be a master of rewriting them.

Subject of Research: Enzymatic biosynthesis of the anticancer nucleoside analogue 5-azacytidine

Article Title: Enzymatic skeletal editing reaction forming the 1,3,5-triazine core during biosynthesis of the anticancer nucleoside analogue 5-azacytidine

Article References: Enzymatic skeletal editing reaction forming the 1,3,5-triazine core during biosynthesis of the anticancer nucleoside analogue 5-azacytidine. (n.d.). https://doi.org/10.1038/s41929-026-01611-x

Image Credits: AI Generated

DOI: 10.1038/s41929-026-01611-x

Keywords: 5-azacytidine, biosynthesis, natural products, enzymes, skeletal editing, 1,3,5-triazine, anticancer drugs, myelodysplastic syndrome, GTP cyclohydrolase, cupin enzyme, thiamine pyrophosphate, enzyme mechanisms